Zoledronic Acid Hospira
zoledronic acid
zoledronic acid
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor, pharmacist or nurse.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
What Zoledronic Acid Hospira is and what it is used for
What you need to know before you are given Zoledronic Acid Hospira
How Zoledronic Acid Hospira is used
Possible side effects
How to store Zoledronic Acid Hospira
Contents of the pack and other information
The active substance in Zoledronic Acid Hospira is zoledronic acid, which belongs to a group of substances called bisphosphonates. Zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change. It is used:
presence of a tumour. Tumours can accelerate normal bone change in such a way that the release of calcium from bone is increased. This condition is known as tumour-induced hypercalcaemia (TIH).
Follow carefully all instructions given to you by your doctor.
Your doctor will carry out blood tests before you start treatment with Zoledronic Acid Hospira and will check your response to treatment at regular intervals.
if you are breast-feeding.
if you are allergic to zoledronic acid, another bisphosphonate (the group of substances to which zoledronic acid belongs), or any of the other ingredients of Zoledronic Acid Hospira (listed in
section 6).
Talk to your doctor before you are given Zoledronic Acid Hospira:
if you have or have had a kidney problem.
if you have or have had pain, swelling or numbness of the jaw, a feeling of heaviness in the jaw or loosening of a tooth. Your doctor may recommend a dental examination before you start
treatment with Zoledronic Acid Hospira
if you are having dental treatment or are due to undergo dental surgery, tell your dentist that you are being treated with Zoledronic Acid Hospira and inform your doctor about your dental treatment.
While being treated with Zoledronic Acid Hospira, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups.
Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of a condition called osteonecrosis of the jaw.
Patients who are undergoing chemotherapy and/or radiotherapy, who are taking steroids, who are undergoing dental surgery, who do not receive routine dental care, who have gum disease, who are smokers, or who were previously treated with a bisphosphonate (used to treat or prevent bone disorders) may have a higher risk of developing osteonecrosis of the jaw.
Reduced levels of calcium in the blood (hypocalcaemia), sometimes leading to muscle cramps, dry skin, burning sensation, have been reported in patients treated with zoledronic acid. Irregular heart beat (cardiac arrhythmia), seizures, spasm and twitching (tetany) have been reported as secondary to severe hypocalcaemia. In some instances the hypocalcaemia may be life-threatening. If any of these apply to you, tell your doctor straight away. If you have pre-existing hypocalcaemia, it must be corrected before initiating the first dose of Zoledronic Acid Hospira. You will be given adequate calcium and vitamin D supplements.
Zoledronic Acid Hospira can be given to people aged 65 years and over. There is no evidence to suggest that any extra precautions are needed.
Zoledronic Acid Hospira is not recommended for use in adolescents and children below the age of 18 years.
Tell your doctor if you are taking, have recently taken or might take any other medicines. It is especially important that you tell your doctor if you are also taking:
Aminoglycosides (medicines used to treat severe infections), calcitonin (a type of medicine used
to treat post-menopausal osteoporosis and hypercalcaemia), loop diuretics (a type of medicine to treat high blood pressure or oedema) or other calcium-lowering medicines, since the combination of these
with bisphosphonates may cause the calcium level in the blood to become too low.
Thalidomide (a medicine used to treat a certain type of blood cancer involving the bone) or any other medicines which may harm your kidneys.
Any other medicines that also contains zoledronic acid and is used to treat osteoporosis and other non-cancer diseases of the bone, or any other bisphosphonate, since the combined effects
of these medicines taken together with Zoledronic Acid Hospira are unknown.
Anti-angiogenic medicines (used to treat cancer), since the combination of these with Zoledronic Acid Hospira has been associated with an increased risk of osteonecrosis of the jaw
(ONJ).
You should not be given Zoledronic Acid Hospira if you are pregnant. Tell your doctor if you are or think that you may be pregnant.
You must not be given Zoledronic Acid Hospira if you are breast-feeding.
Ask your doctor for advice before taking any medicine while you are pregnant or breast-feeding.
There have been very rare cases of drowsiness and sleepiness with the use of Zoledronic Acid Hospira. You should therefore be careful when driving, using machinery or performing other tasks that need full attention.
This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially “sodium-free”.
Zoledronic Acid Hospira must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein (also referred to as ‘IV’ administration).
Your doctor will recommend that you drink enough water before each treatment to help prevent dehydration.
Carefully follow all the other instructions given to you by your doctor, pharmacist or nurse.
The usual single dose given is 4 mg.
If you have a kidney problem, your doctor will give you a lower dose depending on the severity of your kidney problem.
If you are being treated for the prevention of bone complications due to bone metastases, you will be given one infusion of Zoledronic Acid Hospira every three to four weeks.
If you are being treated to reduce the amount of calcium in your blood, you will normally only be given one infusion of Zoledronic Acid Hospira.
Zoledronic Acid Hospira is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.
Patients whose blood calcium levels are not too high will also be prescribed calcium and vitamin D supplements to be taken each day.
If you have received doses higher than those recommended, you must be carefully monitored by your doctor. This is because you may develop serum electrolyte abnormalities (e.g. abnormal levels of
calcium, phosphorus and magnesium) and/or changes in kidney function, including severe kidney
impairment. If your level of calcium falls too low, you may have to be given supplemental calcium by infusion.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The most common ones are usually mild and will probably disappear after a short time.
Severe kidney impairment (will normally be determined by your doctor with certain specific
blood tests).
Low level of calcium in the blood.
Pain in the mouth, teeth and/or jaw, swelling or non-healing sores inside the mouth or jaw discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. These could be signs of bone damage in the jaw (osteonecrosis). Tell your doctor and dentist immediately if you
experience such symptoms while being treated with Zoledronic Acid Hospira or after stopping treatment.
Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for
postmenopausal osteoporosis. It is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received zoledronic acid.
Severe allergic reaction: shortness of breath, swelling mainly of the face and throat.
As a consequence of low calcium values: irregular heart beat (cardiac arrhythmia; secondary to hypocalcaemia).
A kidney function disorder called Fanconi syndrome (will normally be determined by your doctor with certain urine tests).
As a consequence of low calcium values: seizures, numbness and tetany (secondary to hypocalcaemia).
Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. These could be signs of bone damage in the ear.
− Osteonecrosis has also very rarely been seen occurring with other bones than the jaw, especially the hip or thigh. Tell your doctor immediately if you experience symptoms such as new onset or worsening of aches, pain or stiffness while being treated with Zoledronic Acid Hospira or after stopping treatment.
Headache and a flu-like syndrome consisting of fever, fatigue, weakness, drowsiness, chills and bone, joint and/or muscle ache. In most cases no specific treatment is required and the symptoms disappear after a short time (couple of hours or days).
Gastrointestinal reactions such as nausea and vomiting as well as loss of appetite.
Conjunctivitis.
Low level of red blood cells (anaemia).
Hypersensitivity reactions.
Low blood pressure.
Chest pain.
Skin reactions (redness and swelling) at the infusion site, rash, itching.
High blood pressure, shortness of breath, dizziness, anxiety, sleep disturbances, taste disturbances, trembling, tingling or numbness of the hands or feet, diarrhoea, constipation, abdominal pain, dry mouth.
Low counts of white blood cells and blood platelets.
Low level of magnesium and potassium in the blood. Your doctor will monitor this and take any necessary measures.
Weight increase.
Increased sweating.
Sleepiness.
Blurred vision, tearing of the eye, eye sensitivity to light.
Sudden coldness with fainting, limpness or collapse.
Difficulty in breathing with wheezing or coughing.
Urticaria.
Slow heart beat.
Confusion.
Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone.
Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs)
Flu-like symptoms including arthritis and joint swelling.
Painful redness and/or swelling of the eye.
Fainting due to low blood pressure.
Severe bone, joint and/or muscle pain, occasionally incapacitating.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Your doctor, pharmacist or nurse knows how to store Zoledronic Acid Hospira properly (see section 6).
The active substance of Zoledronic Acid Hospira is zoledronic acid. One vial contains 4 mg zoledronic acid (as monohydrate).
The other ingredients are mannitol, sodium citrate, water for injections.
Zoledronic Acid Hospira is supplied as a liquid concentrate (referred to as a ‘concentrate for solution for infusion’ or ‘sterile concentrate’) in a vial. One vial contains 4 mg of zoledronic acid.
Each pack contains one vial with concentrate.
1050 Bruxelles Belgium
Pfizer Service Company BVBA Hoge Wei 10
1930 Zaventem Belgium
For any further information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Pfizer NV/SA
Tél/Tel: +32 (0) 2 554 62 11
Pfizer Luxembourg SARL filialas Lietuvoje Tel. + 370 52 51 4000
Пфайзер Люксембург САРЛ, Клон България Тел.: +359 2 970 4333
Pfizer, spol. s r.o.
Tel: +420-283-004-111
Pfizer Kft.
Tel: + 36 1 488 37 00
Pfizer ApS
Tlf: + 45 44 20 11 00
Drugsales Ltd
Tel: +356 21 419 070/1/2
PFIZER PHARMA GmbH Tel: +49 (0)30 550055-51000
Pfizer bv
Tel: +31 (0)10 406 43 01
Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7500
Pfizer AS
Tlf: +47 67 52 61 00
Pfizer ΕΛΛΑΣ A.E. Τηλ.: +30 210 6785 800
Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0
Pfizer, S.L.
Tel: +34 91 490 99 00
Pfizer Polska Sp. z o.o. Tel: +48 22 335 61 00
Pfizer
Tél: + 33 (0)1 58 07 34 40
Laboratórios Pfizer, Lda. Tel: +351 21 423 55 00
Pfizer Croatia d.o.o. Tel: +385 1 3908 777
Pfizer România S.R.L. Tel: +40 (0)21 207 28 00
Pfizer Healthcare Ireland Tel: 1800 633 363 (toll free)
+44 (0) 1304 616161
Pfizer Luxembourg SARL
Pfizer, podružnica za svetovanje s področja farmacevtske dejavnosti, Ljubljana
Tel: +386 (0)1 52 11 400
Icepharma hf.
Sími: +354 540 8000
Pfizer Luxembourg SARL, organizačná zložka Tel: +421–2–3355 5500
Pfizer S.r.l.
Pfizer Oy
Tel: +39 06 33 18 21 Puh/Tel: +358 (0)9 430 040
Pharmaceutical Trading Co Ltd Τηλ: 24656165
Pfizer AB
Tel: +46 (0)8 550 520 00
Pfizer Luxembourg SARL filiāle Latvijā Tel.: + 371 670 35 775
Pfizer Limited
Tel: + 44 (0) 1304 616161
To prepare an infusion solution containing 4 mg zoledronic acid, further dilute the Zoledronic Acid Hospira concentrate (5.0 ml) with 100 ml of calcium-free or other divalent cation-free infusion solution. If a lower dose of Zoledronic Acid Hospira is required, first withdraw the appropriate volume as indicated below and then dilute it further with 100 ml of infusion solution. To avoid potential incompatibilities, the infusion solution used for dilution must be either 0.9% w/v sodium chloride solution for injection or 5% w/v glucose solution.
Instructions for preparing reduced doses of Zoledronic Acid Hospira: Withdraw the appropriate volume of the liquid concentrate, as follows:
4.4 ml for 3.5 mg dose
4.1 ml for 3.3 mg dose
3.8 ml for 3.0 mg dose
For single use only. Any unused solution should be discarded. Only clear solution free from particles and discolouration should be used. Aseptic techniques must be followed during the preparation of the infusion.
From a microbiological point of view, the diluted solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C – 8°C. The refrigerated solution should then be equilibrated to room temperature prior to administration.
The solution containing zoledronic acid is given as a single 15-minute intravenous infusion in a separate infusion line. The hydration status of patients must be assessed prior to and following administration of zoledronic acid to ensure that they are adequately hydrated.
Studies with several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with zoledronic acid.
Since no data are available on the compatibility of Zoledronic Acid Hospira with other intravenously administered substances, Zoledronic Acid Hospira must not be mixed with other medicinal products/substances and should always be given through a separate infusion line.
Keep Zoledronic Acid Hospira out of the reach and sight of children.
Do not use Zoledronic Acid Hospira after the expiry date stated on the pack.
The unopened vial does not require any specific storage conditions.
The diluted Zoledronic Acid Hospira infusion solution should be used immediately in order to avoid microbial contamination.